1-O-alpha-D-Glucopyranosyl-d-mannitol dihydrate | 174060-42-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-O-alpha-D-Glucopyranosyl-d-mannitol dihydrate
• 英文别名: (2R,3R,4R,5R)-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,4,5-pentol;dihydrate
• CAS: 174060-42-5
• 化学式: C12H28O13
• 分子量: 380.34
• InChiKey: BTKQLFSKIFGYOF-MASOBFGXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.41
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  203
• 氢给体数：
  11
• 氢受体数：
  13

文献信息

• Orally disintegrating tablets
  申请人：AstraZeneca AB

  公开号：US10729655B2

  公开（公告）日：2020-08-04

  The present invention relates to rapidly disintegrating oral dosage forms, more particularly to rapidly disintegrating tablets containing (1S,2S,3R,5S)-3-[7-[1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5 5-(2-hydroxyethoxy)cyclopentane-1,2-diol and a disintegrating excipient. Blister packs suitable for use with the rapidly disintegrating oral dosage form are also disclosed.

  本发明涉及快速崩解口服剂型，特别是含有(1S,2S,3R,5S)-3-[7-[1R,2S)-2-(3、5-(丙硫基)-3H-[1,2,3]-三唑并[4,5-d]嘧啶-3-基]-5 5-(2-羟乙氧基)环戊烷-1,2-二醇和一种崩解赋形剂。还公开了适用于快速崩解口服剂型的泡罩包装。
• Carvedilol-hydrophilic solutions
  申请人：——

  公开号：US20010036959A1

  公开（公告）日：2001-11-01

  The present invention is concerned with pharmaceutically acceptable compositions comprising carvedilol or a pharmaceutically acceptable salt thereof distributed as a molecular dispersion in a concentration above 5% (wt./wt.), as well as pharmaceutical administration forms comprising such compositions and their use for the treatment and/or prophylaxis of illnesses such as hypertension, cardiac insufficiency or angina pectoris.

  本发明涉及包含卡维地洛或其药学上可接受的盐的药学上可接受的组合物，其分子分散体的浓度高于5%（重量/重量），以及包含此类组合物的给药形式及其用于治疗和/或预防高血压、心功能不全或心绞痛等疾病的用途。
• Pseudopolymorphic forms of carvedilol
  申请人：——

  公开号：US20030119893A1

  公开（公告）日：2003-06-26

  The present invention is concerned with pseudopolymorphic forms of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole (carvedilol) or of optically active forms or pharmaceutically acceptable salts thereof, processes for the preparation thereof and pharmaceutical compositions containing them.

  本发明涉及 1-(4-咔唑基氧基)-3-[2-(2-甲氧基苯氧基)乙基氨基]-2-丙醇（卡维地洛）或其光学活性形式或药学上可接受的盐、其制备工艺和含有它们的药物组合物的假多晶型。
• CRYSTALLIZATION OF GLUCOPYRANOSYLALDITOLS, CRYSTALLINE GLUCOPYRANOSYLALDITOL PRODUCT AND USE THEREOF
  申请人：Danisco Sweeteners Oy

  公开号：EP1173453B1

  公开（公告）日：2004-06-30
• HYDROPHILIC MOLECULAR DISPERSE SOLUTIONS OF CARVEDILOL
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1272179A1

  公开（公告）日：2003-01-08